Holen Sie sich die Stockscreener-App
2.05
8.41%
-0.21
Handel nachbörslich:
2.05
Schlusskurs vom Vortag:
$2.26
Offen:
$2.3
24-Stunden-Volumen:
1.75M
Relative Volume:
0.90
Marktkapitalisierung:
$198.67M
Einnahmen:
$20.76M
Nettoeinkommen (Verlust:
$-132.49M
KGV:
-0.7678
EPS:
-2.67
Netto-Cashflow:
$-108.55M
1W Leistung:
-19.77%
1M Leistung:
-17.20%
6M Leistung:
+38.93%
1J Leistung:
-48.89%
1-Tages-Spanne:
$2.0401
$2.30
1-Wochen-Bereich:
$2.0401
$2.6899
52-Wochen-Spanne:
$1.085
$4.26
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Firmenname
C 4 Therapeutics Inc
Sektor
Branche
Telefon
(617) 231-0700
Adresse
490 ARSENAL WAY, WATERTOWN
Vergleichen Sie CCCC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.05 | 219.03M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Eingeleitet | TD Cowen | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-15 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2024-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Equal-Weight |
| 2024-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-13 | Hochstufung | Stifel | Hold → Buy |
| 2023-02-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-04-28 | Eingeleitet | Credit Suisse | Underperform |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-10 | Eingeleitet | JP Morgan | Overweight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-11-23 | Eingeleitet | BofA Securities | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-30 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-27 | Eingeleitet | Jefferies | Buy |
Alle ansehen
C 4 Therapeutics Inc Aktie (CCCC) Neueste Nachrichten
Barclays Lowers Price Target for C4 Therapeutics (CCCC) Despite Maintaining Overweight Rating | CCCC Stock News - GuruFocus
C4 Therapeutics Target of Unusually High Options Trading (NASDAQ:CCCC) - MarketBeat
Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price - simplywall.st
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 11, 2025 - BioSpace
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Travere Therapeutics (NASDAQ: TVTX) issues 20,300 new-hire RSUs vesting over four years - Stock Titan
What analysts say about C4 Therapeutics Inc stockEx-Dividend Date Alerts & Budget Friendly Trading Alerts - earlytimes.in
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Hedge Fund Moves: Will C4 Therapeutics Inc stock remain a Wall Street favorite2025 Risk Factors & Free Expert Verified Stock Movement Alerts - moha.gov.vn
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - pharmiweb.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
TD Cowen Begins Coverage on C4 Therapeutics (NASDAQ:CCCC) - MarketBeat
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
This Cloudflare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
TD Cowen Initiates Coverage of C4 Therapeutics (CCCC) with Buy Recommendation - Nasdaq
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – Company Announcement - Financial Times
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (2025-12-01) - Seeking Alpha
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
C4 Therapeutics Reports Q3 2025 Financial Results - MSN
Mineralys Therapeutics reports inducement award under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss - Seeking Alpha
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
C4 Therapeutics files $400M mixed shelf offering - MSN
CCCC SEC FilingsC4 Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - Investing News Network
C4 Therapeutics (NASDAQ: CCCC) fireside chat at Evercore conference Dec. 3 2025 - Stock Titan
C4 Therapeutics Inc files for mixed shelf of up to $400 millionSEC filing - marketscreener.com
[S-3] C4 Therapeutics, Inc. Shelf Registration Statement | CCCC SEC FilingForm S-3 - Stock Titan
Finanzdaten der C 4 Therapeutics Inc-Aktie (CCCC)
Umsatz
Nettogewinn
Free Cashflow
ENV
C 4 Therapeutics Inc-Aktie (CCCC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Boyle Scott N | Chief Business Officer |
Feb 14 '25 |
Sale |
3.15 |
490 |
1,544 |
110,842 |
0.03%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):